Accendra Health AI Stock Analysis
Want to see ACCH full AI Analyst Report?
Accendra Health (ACCH) AI Stock Analysis
Accendra Health
(Other OTC:ACCH)
ACH scores low primarily due to high fundamental risk (negative equity, revenue decline, and continued losses) and a sharply bearish technical setup (price far below moving averages with negative MACD). Offsetting factors are limited to improved recent cash generation and liquidity/turnaround initiatives discussed on the earnings call, but these are tempered by reduced EBITDA guidance and ongoing operational underperformance.
Accendra Health (ACCH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.49M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.96M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.36
- Revenue Growth
- -61.96%
- EPS Growth
- 87.15%
- Country
- US
- Employees
- 6,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Accendra Health Business Overview & Revenue Model
Company Description
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, includi...
Accendra Health Financial Statement Overview
Summary
Operations show stabilization (losses narrowed vs. 2024–2025) and TTM free cash flow is positive (~$121M), but overall fundamentals remain weak: TTM revenue declined (-3.6%), net margin is still negative (~-6.7%), and the balance sheet is high risk with negative stockholders’ equity (reduced financial flexibility despite lower total debt).
Income Statement
34NegativeBalance Sheet
18Very NegativeCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.55B | 2.76B | 10.70B | 10.33B | 9.96B | 9.79B |
| Gross Profit | 1.13B | 1.29B | 2.22B | 2.13B | 1.83B | 1.51B |
| EBITDA | 141.09M | 219.75M | 51.22M | 390.57M | 368.45M | 415.46M |
| Net Income | -171.56M | -1.10B | -362.69M | -41.30M | 22.39M | 221.59M |
Balance Sheet | ||||||
| Total Assets | 2.08B | 2.45B | 4.66B | 5.09B | 5.39B | 3.54B |
| Cash, Cash Equivalents and Short-Term Investments | 26.61M | 281.99M | 49.38M | 243.04M | 69.47M | 55.71M |
| Total Debt | 1.85B | 2.23B | 2.14B | 2.41B | 2.79B | 1.15B |
| Total Liabilities | 2.65B | 2.91B | 4.09B | 4.17B | 4.44B | 2.60B |
| Stockholders Equity | -568.23M | -460.98M | 565.23M | 924.17M | 945.60M | 938.50M |
Cash Flow | ||||||
| Free Cash Flow | -163.83M | -303.12M | -66.67M | 532.82M | 158.42M | 74.49M |
| Operating Cash Flow | -25.31M | -101.79M | 161.50M | 740.71M | 325.01M | 124.18M |
| Investing Cash Flow | 313.45M | 144.42M | -116.53M | -137.25M | -1.80B | -53.63M |
| Financing Cash Flow | -307.79M | 188.08M | -267.60M | -417.33M | 1.50B | -129.48M |
Accendra Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACCH, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.45, and below the 200-day MA of 2.11, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 18.07 is Positive, neither overbought nor oversold. The STOCH value of 1.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACCH.
Accendra Health Risk Analysis
Accendra Health disclosed 39 risk factors in its most recent earnings report. Accendra Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAccendra Health Peers Comparison
Overall Rating
MEDS43Neutral
ACCH41Neutral
YI40Underperform
RDGT33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $4.23M | -0.04 | 356.14% | ― | -77.47% | 62.15% | |
| 41Neutral | $1.49M | -0.04 | 33.56% | ― | -61.96% | 87.15% | |
| 40Underperform | $24.50M | -1.56 | 23.64% | ― | -23.90% | -45.45% | |
| 33Underperform | $3.74M | -0.00 | -3.54% | ― | 10.16% | 98.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ACCH | Accendra Health Inc | 0.02 | -2.58 | -99.27% | |
| RDGT | Ridgetech, Inc. | 1.03 | -624.47 | -99.84% | |
| AHG | Akso Health Group Sponsored ADR | 1.36 | -0.18 | -11.82% | |
| YI | 111, Inc. | 2.79 | -0.90 | -24.44% | |
| HKPD | Hong Kong Pharma Digital Technology Holdings Ltd. | 1.33 | -19.07 | -93.48% | |
| MEDS | Datameds Ai, Inc. | 0.74 | -23.69 | -96.97% |
Accendra Health Corporate Events
Accendra Health Reports Weak Third-Quarter Financial Results
NegativeOn November 5, 2026, Accendra Health reported third-quarter results for continuing operations for the period ended September 30. Net revenue fell to $601.8 million from $697.3 million a year earlier, while the GAAP loss widened to $18.0 million from...
Accendra Health Executive Transitions to Strategic Advisor Role
NeutralOn October 29, 2026, Perry A. Bernocchi, the company’s executive vice president and chief operating officer, entered into a transition agreement concerning his move from executive officer duties to Strategic Advisor to the Chief Executive Officer. Th...
Accendra Health Extends $150 Million Receivables Program to 2029
PositiveOn October 29, 2026, Accendra Funding LLC and Byram Healthcare Centers, wholly owned subsidiaries of Accendra Health, amended the company’s receivables purchase agreement. The amendment extended the $150 million receivables sale program’s scheduled t...
Accendra Health Outlines Plan to Regain NYSE Compliance
NegativeOn October 27, 2026, Accendra Health received notice from the New York Stock Exchange that it was no longer in compliance with listing standards requiring both an average market capitalization and stockholders’ equity of at least $50 million over a 3...
Accendra Health Addresses NYSE Listing Price Deficiency
NegativeOn October 6, 2026, Accendra Health received notice from the New York Stock Exchange that its common stock no longer met the exchange’s continued listing standard requiring an average closing price of at least $1 over a consecutive 30‑day trading per...
Accendra Health appoints new CEO and commercial chief
PositiveOn September 17, 2026, Accendra Health named board member Kenneth Gardner-Smith as its next President and Chief Executive Officer, with his transition into the role expected early in the fourth quarter of 2026. He will succeed long-serving CEO Edward...
Accendra Health Halts Equity Program, Highlights Liquidity Strength
PositiveOn August 17, 2026, Accendra Health announced it will not proceed with a planned at-the-market equity issuance program that was intended to modestly reduce debt, saying the decision, driven by market conditions, will not affect its results or guidanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
